MX2015012628A - Compuestos de tetrahidropirrolotiazina. - Google Patents
Compuestos de tetrahidropirrolotiazina.Info
- Publication number
- MX2015012628A MX2015012628A MX2015012628A MX2015012628A MX2015012628A MX 2015012628 A MX2015012628 A MX 2015012628A MX 2015012628 A MX2015012628 A MX 2015012628A MX 2015012628 A MX2015012628 A MX 2015012628A MX 2015012628 A MX2015012628 A MX 2015012628A
- Authority
- MX
- Mexico
- Prior art keywords
- tetrahydropyrrolothiazine
- compounds
- tetrahydropyrrolothiazine compounds
- compound
- formula
- Prior art date
Links
- NDYYBQHNPPJCSU-UHFFFAOYSA-N 2,3,4,4a-tetrahydropyrrolo[2,3-e]thiazine Chemical class S1NCCC2N=CC=C21 NDYYBQHNPPJCSU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención proporciona un compuesto de Fórmula (I): en donde R es H o F; y A es: (A), (B), (C) o (D); o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361776819P | 2013-03-12 | 2013-03-12 | |
| PCT/US2014/020070 WO2014143579A1 (en) | 2013-03-12 | 2014-03-04 | Tetrahydropyrrolothiazine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015012628A true MX2015012628A (es) | 2016-07-07 |
Family
ID=50382615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012628A MX2015012628A (es) | 2013-03-12 | 2014-03-04 | Compuestos de tetrahidropirrolotiazina. |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US8841293B1 (es) |
| EP (1) | EP2970336B1 (es) |
| JP (1) | JP6095844B2 (es) |
| KR (1) | KR101688761B1 (es) |
| CN (1) | CN105026404B (es) |
| AP (1) | AP2015008713A0 (es) |
| AR (1) | AR094918A1 (es) |
| BR (1) | BR112015018738A8 (es) |
| CA (1) | CA2898500C (es) |
| CL (1) | CL2015002529A1 (es) |
| CR (1) | CR20150418A (es) |
| CY (1) | CY1119585T1 (es) |
| DK (1) | DK2970336T3 (es) |
| EA (1) | EA026006B1 (es) |
| ES (1) | ES2653421T3 (es) |
| HR (1) | HRP20171851T1 (es) |
| HU (1) | HUE037487T2 (es) |
| IL (1) | IL240903B (es) |
| JO (1) | JO3317B1 (es) |
| LT (1) | LT2970336T (es) |
| MA (1) | MA38390B1 (es) |
| ME (1) | ME02910B (es) |
| MX (1) | MX2015012628A (es) |
| MY (1) | MY180083A (es) |
| NO (1) | NO3039297T3 (es) |
| NZ (1) | NZ712207A (es) |
| PE (1) | PE20151542A1 (es) |
| PH (1) | PH12015502031B1 (es) |
| PL (1) | PL2970336T3 (es) |
| PT (1) | PT2970336T (es) |
| RS (1) | RS56645B1 (es) |
| SG (1) | SG11201507499XA (es) |
| SI (1) | SI2970336T1 (es) |
| TN (1) | TN2015000340A1 (es) |
| TW (1) | TWI593692B (es) |
| UA (1) | UA112941C2 (es) |
| WO (1) | WO2014143579A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014030473A2 (pt) | 2012-06-13 | 2017-06-27 | Hoffmann La Roche | novo diazaespirocicloalcano e azaespirocicloalcano |
| EA036630B1 (ru) | 2012-09-25 | 2020-12-02 | Ф. Хоффманн-Ля Рош Аг | Бициклические производные |
| WO2014066132A1 (en) | 2012-10-26 | 2014-05-01 | Eli Lilly And Company | Bace inhibitors |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| WO2015078803A1 (en) | 2013-11-26 | 2015-06-04 | F. Hoffmann-La Roche Ag | NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL |
| TWI684452B (zh) | 2014-03-14 | 2020-02-11 | 美國禮來大藥廠 | 胺基噻嗪化合物 |
| CR20160419A (es) | 2014-03-26 | 2016-11-07 | Hoffmann La Roche | Nuevos compuestos biciclicos |
| SG11201607845RA (en) | 2014-03-26 | 2016-10-28 | Hoffmann La Roche | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| TWI570127B (zh) * | 2014-09-15 | 2017-02-11 | 美國禮來大藥廠 | 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物 |
| TWI599358B (zh) * | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| TWI574969B (zh) * | 2015-01-30 | 2017-03-21 | 美國禮來大藥廠 | 甲苯磺酸鹽 |
| AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| AR104241A1 (es) | 2015-04-29 | 2017-07-05 | Lilly Co Eli | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |
| JP6886967B2 (ja) | 2015-09-04 | 2021-06-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | フェノキシメチル誘導体 |
| CN107614505B (zh) | 2015-09-24 | 2021-05-07 | 豪夫迈·罗氏有限公司 | 作为双重atx/ca抑制剂的新型二环化合物 |
| BR112018006080A2 (pt) | 2015-09-24 | 2018-10-09 | F. Hoffmann-La Roche Ag | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| BR112018006034A2 (pt) | 2015-09-24 | 2018-10-09 | Hoffmann La Roche | compostos bicíclicos como inibidores de atx |
| RU2018114289A (ru) | 2015-09-24 | 2019-10-24 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов аутотаксина (atx) |
| TW201740954A (zh) * | 2016-03-16 | 2017-12-01 | 美國禮來大藥廠 | 組合療法 |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| AU2017376445B2 (en) * | 2016-12-15 | 2021-09-30 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| MA52722A (fr) | 2016-12-15 | 2021-04-14 | Amgen Inc | Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation |
| US11021493B2 (en) | 2016-12-15 | 2021-06-01 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
| JP7149272B2 (ja) | 2016-12-15 | 2022-10-06 | アムジエン・インコーポレーテツド | β－セクレターゼ阻害剤としてのチアジン誘導体および使用方法 |
| WO2018112086A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| AU2018233079B9 (en) | 2017-03-16 | 2021-07-22 | F. Hoffmann-La Roche Ag | Heterocyclic compounds useful as dual ATX/CA inhibitors |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284957A (en) * | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| AU2003219955A1 (en) * | 2002-03-22 | 2003-10-13 | Eli Lilly And Company | Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists |
| SG162790A1 (en) | 2005-06-14 | 2010-07-29 | Schering Corp | Aspartyl protease inhibitors |
| EP2597087B1 (en) | 2005-10-25 | 2016-03-30 | Shionogi&Co., Ltd. | Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| CA2711655C (en) | 2008-01-18 | 2013-03-05 | Eisai R&D Management Co., Ltd. | Condensed aminodihydrothiazine derivative |
| PE20091834A1 (es) | 2008-04-22 | 2009-12-19 | Schering Corp | Compuestos de 2-imino-3-metilpirrolopirimidinona tiofenilo-sustituida como inhibidores de bace-1 y composiciones que los contienen |
| TWI431004B (zh) * | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| KR20130018370A (ko) | 2008-06-13 | 2013-02-20 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
| MX2011003189A (es) | 2008-09-30 | 2011-04-27 | Eisai R&D Man Co Ltd | Nuevo derivado de aminodihidrotiazina fusionada. |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| US20120245155A1 (en) | 2009-12-11 | 2012-09-27 | Shionogi & Co., Ltd. | Fused heterocyclic compound having amino group |
| GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101140D0 (en) * | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| US8598161B2 (en) | 2011-05-24 | 2013-12-03 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| JO3143B1 (ar) * | 2012-04-03 | 2017-09-20 | Lilly Co Eli | مركبات تتراهيدرو بيرولو ثيازين |
-
2014
- 2014-02-26 TW TW103106569A patent/TWI593692B/zh not_active IP Right Cessation
- 2014-02-27 AR ARP140100629A patent/AR094918A1/es unknown
- 2014-02-27 JO JOP/2014/0061A patent/JO3317B1/ar active
- 2014-03-04 MA MA38390A patent/MA38390B1/fr unknown
- 2014-03-04 KR KR1020157024588A patent/KR101688761B1/ko not_active Expired - Fee Related
- 2014-03-04 ME MEP-2017-252A patent/ME02910B/me unknown
- 2014-03-04 EA EA201591491A patent/EA026006B1/ru not_active IP Right Cessation
- 2014-03-04 CA CA2898500A patent/CA2898500C/en not_active Expired - Fee Related
- 2014-03-04 JP JP2016500566A patent/JP6095844B2/ja active Active
- 2014-03-04 PT PT147128755T patent/PT2970336T/pt unknown
- 2014-03-04 HR HRP20171851TT patent/HRP20171851T1/hr unknown
- 2014-03-04 SG SG11201507499XA patent/SG11201507499XA/en unknown
- 2014-03-04 PL PL14712875T patent/PL2970336T3/pl unknown
- 2014-03-04 LT LTEP14712875.5T patent/LT2970336T/lt unknown
- 2014-03-04 MX MX2015012628A patent/MX2015012628A/es unknown
- 2014-03-04 AP AP2015008713A patent/AP2015008713A0/xx unknown
- 2014-03-04 WO PCT/US2014/020070 patent/WO2014143579A1/en active Application Filing
- 2014-03-04 DK DK14712875.5T patent/DK2970336T3/da active
- 2014-03-04 MY MYPI2015703056A patent/MY180083A/en unknown
- 2014-03-04 ES ES14712875.5T patent/ES2653421T3/es active Active
- 2014-03-04 CN CN201480014295.6A patent/CN105026404B/zh active Active
- 2014-03-04 RS RS20171243A patent/RS56645B1/sr unknown
- 2014-03-04 PE PE2015001901A patent/PE20151542A1/es active IP Right Grant
- 2014-03-04 SI SI201430430T patent/SI2970336T1/sl unknown
- 2014-03-04 US US14/195,897 patent/US8841293B1/en active Active
- 2014-03-04 NZ NZ71220714A patent/NZ712207A/en not_active IP Right Cessation
- 2014-03-04 BR BR112015018738A patent/BR112015018738A8/pt not_active Application Discontinuation
- 2014-03-04 EP EP14712875.5A patent/EP2970336B1/en active Active
- 2014-03-04 HU HUE14712875A patent/HUE037487T2/hu unknown
- 2014-04-03 UA UAA201508698A patent/UA112941C2/uk unknown
- 2014-08-07 US US14/453,855 patent/US8987254B2/en active Active
- 2014-08-12 NO NO14799063A patent/NO3039297T3/no unknown
-
2015
- 2015-02-19 US US14/626,320 patent/US20150157641A1/en not_active Abandoned
- 2015-08-10 TN TN2015000340A patent/TN2015000340A1/en unknown
- 2015-08-14 CR CR20150418A patent/CR20150418A/es unknown
- 2015-08-27 IL IL240903A patent/IL240903B/en not_active IP Right Cessation
- 2015-09-09 CL CL2015002529A patent/CL2015002529A1/es unknown
- 2015-09-10 PH PH12015502031A patent/PH12015502031B1/en unknown
-
2017
- 2017-11-09 CY CY20171101177T patent/CY1119585T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502031B1 (en) | Tetrahydropyrrolothiazine compounds | |
| PH12016500467B1 (en) | Aminoheteroarlyl benzamides as kinase inhibitors | |
| MA39749A (fr) | Dérivés de pipéridine-dione | |
| PH12017501523A1 (en) | Selective bace1 inhibitors | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| RS54730B1 (sr) | Inhibitori beta sekretaze | |
| IN2015DN00598A (es) | ||
| MX2015017156A (es) | Inhibidores de bace. | |
| EA201690911A1 (ru) | Соединения диметилбензойной кислоты | |
| EA201690894A1 (ru) | Феноксиэтилы | |
| MX2015015841A (es) | Compuestos de fenoxietil dihidro-1h-isoquinolina. | |
| IN2014DN07996A (es) | ||
| MX2016010973A (es) | Compuestos de aminocarbonilcarbamato. | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| MX2015008829A (es) | Momelotinib deuterado. | |
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| AU2016330503A8 (en) | Therapeutic compounds and methods of use thereof | |
| MX2016007985A (es) | Compuestos de fluorofenilpirazol. | |
| GB201020397D0 (en) | Compounds | |
| PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
| EA201690593A1 (ru) | Новые соединения мочевины | |
| EA201690908A1 (ru) | Пиразолопиримидиновые соединения | |
| MX2015012610A (es) | Pacritinib deuterizado. | |
| IN2013MU02010A (es) |